Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

45.40
BRL
-1.00
(-2.16%)
5.14EPS
12.36P/E
175.47BMarket Cap
Feb 18Next Earn
Alnylam Pharmaceuticals, Inc.
B3:A1LN34
(B3)

Recent

price

45.40

P/E

ratio

12.36

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
0.12
0.1
0.07
0.04
0.03
0.02
0.03
0.05
0.04
0.1
0.21
0.36
0.43
0.73
0.88
1.42
1.89
Revenue per Share
-0.05
-0.07
-0.11
-0.07
-0.24
-0.17
-0.24
-0.27
-0.38
-0.41
-0.37
-0.36
-0.47
-0.18
-0.11
0.12
1.03
Basic EPS, GAAP
-0.11
-0.1
-0.12
-0.06
-0.12
-0.12
-0.22
-0.27
-0.34
-0.19
-0.3
-0.3
-0.25
0.02
-0.02
0.18
0.28
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.19
0.14
0.13
0.21
0.61
0.74
0.54
0.89
0.64
0.64
0.44
0.25
-0.06
-0.09
0.03
0.3
1.35
Book Value per Share
0.19
0.14
0.13
0.21
0.61
0.74
0.54
0.89
0.64
0.64
0.44
0.25
-0.06
-0.09
0.03
0.3
1.35
Tangible Book Value per Share
839
846
1,004
1,228
1,482
1,676
1,708
1,807
2,007
2,181
2,295
2,364
2,428
2,493
2,547
2,614
2,657
Basic Weighted Avg Shares
100
83
67
47
51
41
47
90
75
220
493
844
1,037
1,828
2,248
3,714
5,013
Sales/Revenue/Turnover
-43.72
-66.24
-95.27
-197.05
-364.34
-720.27
-900.33
-556.2
-1,087.56
-427.5
-168.09
-83.93
-75.68
-15.43
-7.87
13.51
19.5
Operating Margin (%)
5
5
9
10
12
19
15
12
15
54
74
90
44
54
57
56
55
Depreciation Expense
-44
-58
-106
-89
-360
-290
-410
-491
-761
-886
-858
-853
-1,131
-440
-278
314
2,724
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.91
- -
Effective Tax Rate (%)
-43.5
-69.66
-158.88
-189.17
-712.79
-705.83
-869.63
-545.95
-1,016.58
-403.24
-174.15
-101.01
-109.04
-24.08
-12.37
8.45
54.34
Profit Margin (%)
152
71
77
200
651
1,043
540
1,620
1,021
1,363
2,030
2,113
1,924
2,015
2,109
2,584
3,050
Working Capital
- -
- -
- -
- -
- -
- -
150
30
30
276
484
957
1,278
1,264
1,254
1,233
854
LT Debt
158
118
134
270
936
1,265
920
1,766
1,302
1,439
1,016
588
-158
-221
67
789
3,604
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
28.39
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
32.59
- -
Return on Capital (%)
-25.89
-41.74
-84.12
-44.13
-59.74
-26.36
-37.54
-36.54
-49.63
-64.66
-69.92
-106.31
- -
- -
- -
73.28
141.97
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
46
46
408
LT Borrowings
1,009
1,011
651
LT Finance Leases
218
210
203
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,663
2,669
2,672
Market Capitalization
43,004
39,586
33,858

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,219
4,620
5,113
Cash, Cash Equivalents & STI
3,009
3,308
3,587
Accounts Receivable, Net
884
913
1,085
Inventories
84
97
106
Total Current Liabilities
1,349
1,513
2,063
Payables & Accruals
1,073
1,204
1,372
ST Debt
46
46
408
Deferred Revenue
3
4
12

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
83.59%
163.27%
1,076.33%
Free Cash Flow
-132.99%
-302.18%
-1,192.73%
Net Income, GAAP
-14.93%
-55.74%
-212.79%
Sales/Revenue/Turnover
66.49%
51.72%
65.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
494
660
501
593
2,248
2025
594
774
1,249
1,097
3,714
2026
1,167
1,291
1,458
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.01
-0.04
-0.03
-0.11
2025
-0.01
-0.03
0.11
0.07
0.12
2026
0.08
0.06
0.81
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Alnylam Pharmaceuticals, Inc. (ALNY) develops and commercializes RNA interference (RNAi) therapeutics targeting genetically defined diseases; core products include ONPATTRO (patisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, AMVUTTRA (vutrisiran) for ATTR amyloidosis with polyneuropathy or cardiomyopathy, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1; the company also advances partnered programs such as Leqvio (inclisiran) for hypercholesterolemia marketed by Novartis. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam operates globally with key facilities in the US, Europe (including France, Italy, Netherlands, Sweden, Switzerland, and the UK), and Japan. The company maintains strategic collaborations with Roche on zilebesiran for hypertension, Regeneron for CNS diseases, Sanofi on fitusiran for hemophilia, and others including Novartis and Agios Pharmaceuticals. Recent developments encompass expansion of AMVUTTRA into ATTR cardiomyopathy with strong launch uptake and upgraded 2025 revenue guidance, initiation of a Phase 1 trial for ALN-4324 targeting GRB14 for type 2 diabetes, and Agios' IND clearance for AG-236 (ALN-TMP) in polycythemia vera; Alnylam joined the Alliance for Genomic Discovery in 2025 to leverage datasets for gene-silencing medicines and extended its partnership with Medison Pharma into LATAM and APAC markets. Pipeline advancements feature nucresiran for ATTR amyloidosis, mivelsiran for Alzheimer's disease and cerebral amyloid angiopathy, and positive Phase 3 data for zilebesiran. These efforts support Alnylam's transition to profitability with 2024 net product revenues exceeding $1.3 billion across rare and cardiometabolic indications.

Company News

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

  • Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD

  • Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

  • Brown Advisory Large-Cap Sustainable Growth Strategy Q3 2026 Holdings Performance

  • Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership

  • Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

  • Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More

  • ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

  • Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop

  • Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript

  • Alnylam Pharmaceuticals Q3 Earnings Call Highlights

  • Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

  • Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics

  • Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

  • Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

  • Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

  • Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial

  • Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case

  • Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease